Literature DB >> 17593631

Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines.

Laura Breen1, Mary Heenan, Verena Amberger-Murphy, Martin Clynes.   

Abstract

BACKGROUND: p53 is a tumour suppressor gene, which is mutated in more than half of all tumours. Most chemotherapeutic drugs cause DNA damage, which is sensed by p53; the cell can then try to repair the damage or induce cell suicide. If the p53 machinery is defective, effective chemotherapy is made more difficult.
MATERIALS AND METHODS: Wild-type p53 was transfected into lung cancer cell lines with different p53 status. The transfected cells were tested for changes in sensitivity to a range of chemotherapeutic agents.
RESULTS: We observed only modest changes in the sensitivity to the chemotherapeutic agents adriamycin, taxol and carboplatin in the transfected cells lines. p53 protein was detected in a transfected clone of the cell line H1299, whose parent cells are p53 null. However, the protein did not accumulate after DNA damage, suggesting that this cell line utilises alternative pathways for responding to stress, and no longer has a functional p53 pathway.
CONCLUSION: The results suggest that introduction of wild-type p53 alone is not sufficient to substantially alter the sensitivity of a cell line to a given chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593631

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells.

Authors:  Quan-Xiang Wei; Franciscus van der Hoeven; Monica Hollstein; Adam F Odell
Journal:  Nat Protoc       Date:  2012-05-17       Impact factor: 13.491

2.  Deguelin induces PUMA-mediated apoptosis and promotes sensitivity of lung cancer cells (LCCs) to doxorubicin (Dox).

Authors:  Aimei Wang; Weina Wang; Yaqi Chen; Fengqiao Ma; Xiaoming Wei; Yongyi Bi
Journal:  Mol Cell Biochem       Date:  2017-10-13       Impact factor: 3.396

3.  The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.

Authors:  Olga A Patutina; Nadezda L Mironova; Nelly A Popova; Vasily I Kaledin; Valery P Nikolin; Valentin V Vlassov; Marina A Zenkova
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

Review 4.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

5.  Podophyllotoxin acetate triggers anticancer effects against non-small cell lung cancer cells by promoting cell death via cell cycle arrest, ER stress and autophagy.

Authors:  Jae Yeon Choi; Wan Gi Hong; Jeong Hyun Cho; Eun Mi Kim; Jongdoo Kim; Chan-Hun Jung; Sang-Gu Hwang; Hong-Duck Um; Jong Kuk Park
Journal:  Int J Oncol       Date:  2015-08-13       Impact factor: 5.650

6.  Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.

Authors:  Maciej Serda; Danuta S Kalinowski; Nathalie Rasko; Eliška Potůčková; Anna Mrozek-Wilczkiewicz; Robert Musiol; Jan G Małecki; Mieczysław Sajewicz; Alicja Ratuszna; Angelika Muchowicz; Jakub Gołąb; Tomáš Simůnek; Des R Richardson; Jaroslaw Polanski
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

7.  18F-fludrodeoxyglucose maximal standardized uptake value and metabolic tumor burden are associated with major chemotherapy-related tumor markers in NSCLC patients.

Authors:  Lu Bai; Chihua Guo; Jiansheng Wang; Xiang Liu; Yang Li; Miao Li; Youmin Guo; Xiaoyi Duan
Journal:  Onco Targets Ther       Date:  2016-10-14       Impact factor: 4.147

8.  PATZ1 induces PP4R2 to form a negative feedback loop on IKK/NF-κB signaling in lung cancer.

Authors:  Ming-Yi Ho; Chi-Ming Liang; Shu-Mei Liang
Journal:  Oncotarget       Date:  2016-08-09

9.  A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.

Authors:  Kenneth S Chen; Woo Sun Kwon; Jiwoong Kim; Su Jin Heo; Hyo Song Kim; Hyo Ki Kim; Soo Hee Kim; Won Suk Lee; Hyun Cheol Chung; Sun Young Rha; Tae Hyun Hwang
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-09

10.  Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.

Authors:  Samer Alzoubi; Leigh Brody; Sunniyat Rahman; Anne-Laure Mahul-Mellier; Nicolas Mercado; Kazuhiro Ito; Mona El-Bahrawy; Andrew Silver; Alan Boobis; Jimmy D Bell; Nabil Hajji
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.